Hansard
Consult the user guide
For assistance, please contact us
Consult the user guide
For assistance, please contact us
Add search criteria
Results: 1 - 30 of 763
View Salma Zahid Profile
Lib. (ON)
View Salma Zahid Profile
2020-11-26 10:06 [p.2481]
Mr. Speaker, I have the honour to present, in both official languages, the first and second reports of the Standing Committee on Citizenship and Immigration.
The committee has considered the main estimates, 2020-21, and reports the same. It has also considered the supplementary estimates (B), 2020-21, and reports the same.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 18:55 [p.2563]
Mr. Chair, I will start with brief remarks and then go into questions for the purposes of your timing.
The COVID pandemic has been the greatest crisis in the modern history of our country. It has been a difficult year for Canada, for Canadian families, seniors, small businesses, front-line nurses, PSWs and doctors. Our country has pivoted in remarkable ways.
I want to thank those on our front lines who have been a part of the national response to COVID-19.
The questions we will have for the minister are based on Canada needing to do better. The very hybrid nature of Parliament itself is a result. People are working from home. We have a hybrid structure. The minister will be on a screen today as opposed to in the House where she was earlier today. That is a sign of the hybrid nature of how things are changing.
After months of lockdown, of uncertainty, of businesses failing, of people declaring bankruptcy and of people losing a loved one, a vaccine on the eve of Christmas was the hope for which our country was looking. That hope and that desire for Canada to do well, to recover and to help our people will underline my questions here tonight.
When was the minister first informed, or her office, by company representatives, telling them that the Pfizer vaccine would require specific logistics of a pharmaceutical-grade freezer and cold logistics chain?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, every step of the way, the Department of Health has been working very closely with Procurement Canada, in fact, hand in glove. We have been working with the manufacturer to understand what the requirements are to transport vaccines, store vaccines and, in fact, to deploy vaccines. We are working with provinces and territories right now to ensure everyone is set up for success.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 18:57 [p.2564]
Mr. Chair, my question was when was the minister informed of the extreme cold temperature requirements for the Pfizer vaccine?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, the work of procurement has been integrated with the work of Health Canada as we pursue, acquire and plan to deploy vaccines. I am very proud to say that the whole of government—
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 18:58 [p.2564]
Mr. Chair, this will be long night if we just have more “whole of government” or “our portfolio of vaccines”. Those are the lines we want to get past tonight.
Again to the minister, when was her team informed of the challenges posed by the extreme cold storage requirements for the Pfizer vaccine?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, every step of the way we have negotiated and communicated extensively with the manufacturers of the seven very promising vaccine candidates. Of course, we know the requirements for storing, transporting and deploying. We are working now to have every success with provinces and territories to do that.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 18:58 [p.2564]
Mr. Chair, I will move on. One last time, can I get a date on the cold storage requirements for the Pfizer vaccine?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, we have worked extensively with the pharmaceutical manufacturers to fully understand how best to transport, store and deploy them.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 18:59 [p.2564]
Mr. Chair, moving on, Ford Motor Company has begun to procure the type of specialized freezers to store the Pfizer vaccine.
Can the minister tell the House how many freezers Health Canada has procured to store the Pfizer vaccine?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, I am so grateful for the work of Procurement Canada that is working hand in glove with Health Canada and indeed the work that we are doing with provinces and territories to understand their capacities and ensure we have the materials available when the vaccine arrives. We are very well along in that process and we are very optimistic about the ability of the provinces and territories to deploy this vaccine.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 18:59 [p.2564]
Mr. Chair, I will let Canadians and journalists watching this committee of the whole know that we will hear a lot of “hand in glove”, “whole of government” and a lot of “robust portfolio” tonight. We want answers to simple questions that are important in the public interest, so I will continue.
Did the government negotiate or attempt to negotiate the right to manufacture the Pfizer vaccine in Canada?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, we have been so well served by the vaccine task force, which is composed of hard-working volunteer Canadians with a variety of expertise in manufacturing of pharmaceuticals, vaccination and virology. That is why we are so well situated, with seven candidates. They are the most promising candidates around the world, a diverse portfolio indeed, and Canadians will be well served by their expertise and leadership.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 19:00 [p.2564]
Mr. Chair, I will ask again. Did the minister, with respect to the Pfizer vaccine, in their great portfolio of vaccines, negotiate the ability to manufacture that vaccine in Canada?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, I am thrilled that Canadians will have such a variety of vaccines. Canada has purchased more vaccine per capita than any other country in the world. We are very confident that the provinces and territories have the expertise they need to deploy the vaccine. We are working with the—
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 19:01 [p.2564]
Mr. Chair, hand in hand, whole of government and grand portfolio; no answers to specific questions. I will move on; no answer on Pfizer.
Did the government negotiate or attempt to negotiate the right to manufacture the Moderna vaccine in Canada?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, the president of Moderna has noted how well situated Canada is to acquire the Moderna vaccine and deploy it. The president has noted that we placed our order early and that we are well situated in our ability to receive Moderna and deploy it successfully in Canada.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 19:02 [p.2564]
Mr. Chair, does the minister think I would actually get answers from perhaps the president of Moderna?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, as the member opposite knows, pharmaceutical companies are working with countries around the world. They have been contracted to provide doses for this global pandemic, and we are thrilled that Moderna has Canada at the top of its list.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 19:02 [p.2564]
Mr. Chair, I hear no answers on the Pfizer vaccine, no specific details on the Moderna vaccine and more reference to a vague portfolio. I am sure it is reassuring, as Canadians will see vaccines rolling out to billions of people around the planet, that we will have a robust portfolio in two years.
On May 12, the government signed an agreement between the National Research Council and CanSino that would “allow the NRC to advance a scale-up production process for a vaccine candidate.”
Did the government have the right to manufacture the CanSino vaccine in Canada?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, I have to say that I am incredibly confident, with the portfolio of vaccines that we have acquired, that we have the right blend of vaccines.
As the member opposite knows, we have vaccines from a variety of different kinds of technology, and we have the capacity, as a leading country in immunization, to deploy these vaccines successfully. This is good news for Canadians.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 19:03 [p.2565]
Mr. Chair, I heard no response to making Pfizer, Moderna or CanSino in Canada, for those following.
The news release from the announcement states that the National Research Council will have “readiness for Canadian bioprocessing of potential vaccine candidates as they become available.”
Did the government originally intend to manufacture multiple vaccine candidates at the NRC site in Montreal?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, as the member opposite knows, our government has been investing in science and research and has been investing in the biomanufacturing sector, and that is exactly what we need to do to combat future pandemics. In terms of vaccination for Canadians, we are thrilled that we have seven such promising candidates, three of them already with Health Canada for regulatory approval.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 19:04 [p.2565]
Mr. Chair, of the seven promising candidates she has referred to several times, did the government negotiate to have any manufactured in Canada?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, in fact, one of the seven is Canadian, Medicago, and that is exciting news, because as we rebuild our biomanufacturing sector, this will hold Canada in good stead for future health crises.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 19:04 [p.2565]
Mr. Chair, on August 5 the government announced the Pfizer and Moderna agreements, well after other countries.
Was the agreement between CanSino and Canada raised in the negotiations with Pfizer and Moderna?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, I have to say that Procurement Canada has been doing incredible work in making sure that Canada is well positioned to purchase the most promising vaccines as they have been recommended by our vaccine task force. Canada is well positioned with more doses per capita than any other country and with a robust experience in immunization. I will say that the provinces and territories—
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 19:05 [p.2565]
Mr. Chair, “robust portfolio” and “whole of government” I think we will determine to be a stock answer too.
Three weeks later, on August 26, the government's deal with CanSino fell apart. Has the Public Health Agency since briefed the minister on the government's lack of ability to domestically manufacture a COVID-19 vaccine?
View Patty Hajdu Profile
Lib. (ON)
Mr. Chair, I think this is a great time to thank the hard-working people at Health Canada, especially the regulators who are working literally 24 hours a day, seven days a week, to make sure that we are analyzing the data of the three promising vaccines that have applied for regulatory approval here in Canada. When the vaccines are ready, Canada will be ready, and this is good news for Canadians.
View Erin O'Toole Profile
CPC (ON)
View Erin O'Toole Profile
2020-11-26 19:06 [p.2565]
Mr. Chair, that was the “whole of government” response. We are looking for actual answers to these questions, and it is disappointing that we are not getting them.
Since the CanSino deal fell apart on August 26, the government has signed deals with AstraZeneca and GlaxoSmithKline. Has the government attempted to negotiate the right to domestically manufacture either of these vaccine candidates?
Results: 1 - 30 of 763 | Page: 1 of 26

1
2
3
4
5
6
7
8
9
10
>
>|
Show both languages
Refine Your Search
Export As: XML CSV RSS

For more data options, please see Open Data